Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

active_not_recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_1

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

NCT06218511
completedphase_2

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

NCT00488592
completedphase_1

Immunotherapy of Melanoma Patients

NCT00112216

Clinical Trials (3)

Showing 3 of 3 trials
NCT06218511Phase 1

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

Active Not Recruiting
NCT00488592Phase 2

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Completed
NCT00112216Phase 1

Immunotherapy of Melanoma Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3